CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
CALGB-30607 CALGB Randomized; Phase III; Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511; IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced; Stage IIIB/IV Non-Small Cell Lung Cancer Adult CIRB - Late Phase Emphasis
CALGB-30610 CALGB Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide Adult CIRB - Late Phase Emphasis
CALGB-30801 CALGB A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Adult CIRB - Late Phase Emphasis
CALGB-40101 CALGB Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study Adult CIRB - Late Phase Emphasis
CALGB-40302 CALGB Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer Adult CIRB - Late Phase Emphasis
CALGB-40502 CALGB A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer<br> Adult CIRB - Late Phase Emphasis
CALGB-40503 CALGB Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized; Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer Adult CIRB - Late Phase Emphasis
CALGB-40601 CALGB Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer Adult CIRB - Late Phase Emphasis
CALGB-49808 CALGB A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002** Adult CIRB - Late Phase Emphasis
CALGB-49907 CALGB A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer Adult CIRB - Late Phase Emphasis